This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/mesh/concept/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01355/identifier/chebi/
n9http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB01355/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01355/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01355/identifier/kegg-compound/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01355/identifier/kegg-drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01355/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01355
rdf:type
n3:Drug
n3:description
A barbiturate that is effective as a hypnotic and sedative. [PubChem]
n3:generalReferences
# Takenoshita R, Toki S: [New aspects of hexobarbital metabolism: stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases] Yakugaku Zasshi. 2004 Dec;124(12):857-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15577260 # Wahlstrom G: A study of the duration of acute tolerance induced with hexobarbital in male rats. Pharmacol Biochem Behav. 1998 Apr;59(4):945-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9586853 # Korkmaz S, Ljungblad E, Wahlstrom G: Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat. Brain Res. 1995 Apr 10;676(2):371-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7614008 # Dall V, Orntoft U, Schmidt A, Nordholm L: Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital. Pharmacol Biochem Behav. 1993 Sep;46(1):73-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8255925
n3:group
approved
n3:indication
For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.
owl:sameAs
n6:DB01355 n9:DB01355
dcterms:title
Hexobarbital
adms:identifier
n12:PA449875 n13:C11723 n14:D01071 n15:5706 n16:DB01355 n17:Hexobarbital
n3:mechanismOfAction
Hexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
n3:synonym
5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione Evipan 5-Cyclohex-1-enyl-1,5-dimethyl-pyrimidine-2,4,6-trione 5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid Hexobarbitone Methexenyl Hexobarbital Methylhexabital
n3:toxicity
Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
n3:proteinBinding
25%
n3:salt
n18:hasConcept
n19:M0010321
n3:IUPAC-Name
n4:271B418D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4193-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4192-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B418F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4190-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4191-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B418B-363D-11E5-9242-09173F13E4C5 n4:271B41A2-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4189-363D-11E5-9242-09173F13E4C5 n4:271B418C-363D-11E5-9242-09173F13E4C5 n4:271B41A4-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B41A5-363D-11E5-9242-09173F13E4C5 n4:271B418A-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B41A6-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:N01AF02 n8:N05CA16
n3:H-Bond-Acceptor-Count
n4:271B4199-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B419A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4194-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4195-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4197-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4196-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4198-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
56-29-1
n3:category
n3:Bioavailability
n4:271B419E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B41A0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B41A1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B41A3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B419D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B419C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B419F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B418E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B419B-363D-11E5-9242-09173F13E4C5